Trial Profile
A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington's disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studies.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Selisistat (Primary)
- Indications Huntington's disease
- Focus Biomarker; Pharmacodynamics
- Acronyms PADDINGTON
- Sponsors Siena Biotech
- 13 Jan 2012 United Kingdom Clinical Research Network reports accrual to date changed from 1% to 11%.
- 02 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2011 Additional lead trial centre, investigator and actual patient no is 55 identified as reported by ClinicalTrials.gov.